Lyra Therapeutics

Lyra Therapeutics company information, Employees & Contact Information

Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.

Company Details

Employees
41
Founded
-
Address
480 Arsenal St, Watertown,massachusetts 02472,united States
Phone
617.393.4600
Email
co****@****atx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Watertown, Massachusetts
Looking for a particular Lyra Therapeutics employee's phone or email?

Lyra Therapeutics Questions

News

Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire

Lyra Therapeutics Announces Clinical Plan for LYR-210 and GlobeNewswire

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - Yahoo Finance

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why Yahoo Finance

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst Seeking Alpha

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate Stocktwits

Why Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket Today - Tokenist

Why Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket Today Tokenist

Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance

Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win Yahoo Finance

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) GlobeNewswire

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer - citybiz

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer citybiz

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

Lyra Therapeutics Posts Corporate Presentation on LYR-210 - TipRanks

Lyra Therapeutics Posts Corporate Presentation on LYR-210 TipRanks

LYRA Stock Price and Chart — NASDAQ:LYRA - TradingView

LYRA Stock Price and Chart — NASDAQ:LYRA TradingView

Lyra Therapeutics (LYRA) Stock Price, News & Analysis - MarketBeat

Lyra Therapeutics (LYRA) Stock Price, News & Analysis MarketBeat

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 GlobeNewswire

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know Yahoo Finance

Lyra Therapeutics Announces Up to Approximately $15 Million - GlobeNewswire

Lyra Therapeutics Announces Up to Approximately $15 Million GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis GlobeNewswire

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development - GlobeNewswire

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development GlobeNewswire

Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index - GlobeNewswire

Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index GlobeNewswire

Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? - InvestorPlace

Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? InvestorPlace

Lyra Therapeutics wants a $58M IPO as biotechs aim to buck volatility - Fierce Biotech

Lyra Therapeutics wants a $58M IPO as biotechs aim to buck volatility Fierce Biotech

Lyra Therapeutics (LYRA) - Zacks Investment Research

Lyra Therapeutics (LYRA) Zacks Investment Research

LYRA News Today | Why did Lyra Therapeutics stock drop today? - MarketBeat

LYRA News Today | Why did Lyra Therapeutics stock drop today? MarketBeat

Top Lyra Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant